[의학신문·일간보사=오인규 기자] At KIMES 2021, MEDICALIP Introduced AI Medical Solutions for Precision Health which are compatible with any types of Medical Images such as CT, MRI, X-rays. The Company presented an AI Body Composition Analysis Solution for preventing Metabolic Diseases and a Respiratory Disease Solution.
MEDICALIP (CEO Park Sang-joon), specializing in medical AI total solution, presented a precision health AI medical solution in preparation for the aging society and the era of new infectious diseases at the 36th Korea International Medical Equipment Show (KIMES 2021).
The company has unveiled its latest medical solution line-up, developed based on medical imaging prediction technology using AI, and actively promote its innovative AI technology that enables disease prevention and monitoring utilizing medical image data acquired from CT and X-ray.
With AI segmentation and 3D modeling of medical imaging technology and data labeling capacity, based on high quality medical images acquired from Seoul National University Hospital and abundant anatomy knowledge from a team of experts, MEDICALIP is further stationing itself as a strong player in the precision health AI industry.
The company has successfully developed numerous medical platforms – AI medical imaging segmentation solution, medical 3D printing simulator, medical AR and VR contents – that can be utilized practically at the medical field by continuously upgrading its technology and products. The company has also been receiving spotlight lately as it has unveiled a series of innovative new products – “DeepCatch,” an automatic body composition analysis software utilizing AI and “TiSepX,” a disease quantification and monitoring solution utilizing X-ray.
MEDICALIP was the third company within the medical imaging segmentation and modeling sector to acquire U.S. FDA approval for its flagship product, “MEDIP PRO,” which is a AI-based medical imaging segmentation software with verified competitiveness and technology of global standard as it has received authorization by both Korea’s Ministry of Food and Drug Safety and Europe’s CE marking.
The product not only enables users to examine organs and lesions more accurately in the body by converting medical images acquired by CT and MRI into 3D modeling, but also maximizes analytic efficiency by segmenting each area in a swift and accurate way utilizing AI technology. Based on such technologies, MEDICALIP aims to diversify its product line-up going forward by targeting numerous illnesses.
Among them, “DeepCatch,” launched late last year to specialize in the research of cancer, obesity, sarcopenia, osteoporosis, metabolic syndrome and other illnesses of the aged, has been adopted by major university hospitals in Korea and international cancer research institutes, and thus leading to an increase in demand within the sector of CT-based body composition research. This is because body composition research, which is closely related to medical prognosis and fatality rate, is being the subject of active research in many countries around the world, especially amid an urgent need to prepare for responses against illnesses of the aged and chronic metabolic disorders due to the aging population.
CT data is uploaded, “DeepCatch” immediately analyzes body composition – skin, bone, muscle, Abdominal visceral fat, subcutaneous fat, internal organs, central nervous system – with 97% accuracy, and delivers an automatic analysis report on the volume and area of muscle and fat, abdominal circumference and body fat percentage. This is an innovative solution that MEDICALIP developed by applying AI medical imaging automatic segmentation technology to “body composition” to contribute to the prevention and research of metabolic disorders globally.
In addition, MEDICALIP unveiled its AI platform “TiSepX” which utilizes X-ray imaging that is most widely used in medical radiology to predict and quantify lung disorders, which also enables the monitoring of treatment efficacy and improvement trend.
“TiSepX” is a product that has been designed to acquire 3D information on the degree of lung damage delivered from 2D X-ray utilizing AI deep learning. Last year, MEDICALIP provided its “TiSepX COVID19,” a platform that quantifies COVID-19 free of charge to contribute to combating the pandemic as almost all countries suffered from -a shortage in medical resources.
At the KIMES 2021, MEDICALIP unveiled "TiSepX TB" which can not only categorize active pulmonary tuberculosis (TB) and latent or inactive TB patients by utilizing AI-based X-ray disease prediction technology but also identify TB activity index to enable the visualization of treatment efficacy.
"TiSepX TB" quantifies the area of the lung that has been damaged by pulmonary TB, enabling easy monitoring of therapeutic treatment efficacy and activity index. Compared to existing AI products that simply diagnose and identify TB infection, the product provides the world's only solution to monitor the treatment efficacy and the disease even after full recovery by utilizing statistical data for active and inactive TB. Therefore, it is expected to be widely used for tuberculosis patients whose treatment progress cannot be monitored easily with the naked eye.
Park Sang-joon, CEO of MEDICALIP says, "I am very delighted to unveil the AI prediction solution, which inevitably took a very long period of time for research. We continue to expand our differentiated product line-up based on the medical AI source technology that has been accumulated for numerous years," adding that "Since most diseases accompany physical changes, accurate measurement of such changes in statistical terms can help the projection and prevention before one becomes ill, and this also enables preemptive response against certain illnesses before patients develop severe symptoms."
Park also expressed confidence by noting that "MEDICALIP has already developed DeepCatch that can be utilized to prevent illnesses of the aged and metabolic disorders based on such precise medical technology as well as TiSepX, an AI solution that enables long-term monitoring of treatment efficacy, which can help the company lay the groundwork to station itself as the top player in prediction AI technology.
He also stressed that he hopes "the KIMES 2021 can become a platform for the company to promote its AI solution to many medical practitioners and people working in the related field, further contributing to a wider application of AI solution in the medical field."
[Meet the on-line version of Medical Newspaper special edition articles that are distributed physically at KIMES 2021]